Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
ACS Pharmacol Transl Sci ; 7(5): 1438-1456, 2024 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-38751618

RESUMO

Interleukin (IL)-1ß is an apex proinflammatory cytokine produced in response to tissue injury and infection. The output of IL-1ß from monocytes and macrophages is regulated not only by transcription and translation but also post-translationally. Release of the active cytokine requires activation of inflammasomes, which couple IL-1ß post-translational proteolysis with pyroptosis. Among inflammasome platforms, NOD-like receptor pyrin domain-containing protein 3 (NLRP3) is implicated in the pathogenesis of numerous human disorders in which disease-specific danger-associated molecular patterns (DAMPS) are positioned to drive its activation. As a promising therapeutic target, numerous candidate NLRP3-targeting therapeutics have been described and demonstrated to provide benefits in the context of animal disease models. While showing benefits, published preclinical studies have not explored dose-response relationships within the context of the models. Here, the preclinical pharmacology of a new chemical entity, [(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide (NT-0249), is detailed, establishing its potency and selectivity as an NLRP3 inhibitor. NT-0249 also is evaluated in two acute in vivo mouse challenge models where pharmacodynamic/pharmacokinetic relationships align well with in vitro blood potency assessments. The therapeutic utility of NT-0249 is established in a mouse model of cryopyrin-associated periodic syndrome (CAPS). In this model, mice express a human gain-of-function NLRP3 allele and develop chronic and progressive IL-1ß-dependent autoinflammatory disease. NT-0249 dose-dependently reduced multiple inflammatory biomarkers in this model. Significantly, NT-0249 decreased mature IL-1ß levels in tissue homogenates, confirming in vivo target engagement. Our findings highlight not only the pharmacological attributes of NT-0249 but also provide insight into the extent of target suppression that will be required to achieve clinical benefit.

2.
J Pharmacol Exp Ther ; 388(3): 813-826, 2024 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-38336379

RESUMO

Systemic and cerebral inflammatory responses are implicated in the pathogenesis of obesity and associated metabolic impairment. While the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome has been linked to obesity-associated inflammation, whether it contributes to the development or maintenance of obesity is unknown. We provide support for a direct role of saturated fatty acids, such as palmitic acid, as NLRP3 activating stimuli in obese states. To investigate whether NLRP3 activation contributes to the pathogenesis of diet-induced obesity (DIO) in mice, we tested two different clinical-stage NLRP3 inflammasome inhibitors. We demonstrate a contributory role of this key inflammasome to established obesity and associated systemic and cerebral inflammation. By comparing their effects to calorie restriction, we aimed to identify specific NLRP3-sensitive mechanisms contributing to obesity-induced inflammation (as opposed to be those regulated by weight loss per se). In addition, a direct comparison of an NLRP3 inhibitor to a glucagon like peptide-1 receptor agonist, semaglutide (Wegovy), in the DIO model allowed an appreciation of the relative efficacy of these two therapeutic strategies on obesity, its associated systemic inflammatory response, and cerebral gliosis. We show that two structurally distinct, NLRP3 inhibitors, NT-0249 and NT-0796, reverse obesity in the DIO mouse model and that brain exposure appears necessary for efficacy. In support of this, we show that DIO-driven hypothalamic glial fibrillary acidic protein expression is blocked by dosing with NT-0249/NT-0796. While matching weight loss driven by semaglutide or calorie restriction, remarkably, NLRP3 inhibition provided enhanced improvements in disease-relevant biomarkers of acute phase response, cardiovascular inflammation, and lipid metabolism. SIGNIFICANCE STATEMENT: Obesity is a global health concern that predisposes individuals to chronic disease such as diabetes and cardiovascular disease at least in part by promoting systemic inflammation. We report that in mice fed a high-fat, obesogenic diet, obesity is reversed by either of two inhibitors of the intracellular inflammatory mediator NLRP3. Furthermore, NLRP3 inhibition reduces both hypothalamic gliosis and circulating biomarkers of cardiovascular disease risk beyond what can be achieved by either the glucagon like peptide-1 agonist semaglutide or calorie restriction alone.


Assuntos
Doenças Cardiovasculares , Inflamassomos , Camundongos , Animais , Inflamassomos/metabolismo , Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismo , Gliose/tratamento farmacológico , Dieta Hiperlipídica/efeitos adversos , Camundongos Endogâmicos NOD , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Obesidade/metabolismo , Redução de Peso , Biomarcadores , Peptídeos Semelhantes ao Glucagon , Camundongos Endogâmicos C57BL
3.
J Pharmacol Exp Ther ; 388(3): 798-812, 2024 02 15.
Artigo em Inglês | MEDLINE | ID: mdl-38253384

RESUMO

The NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome is a central regulator of innate immunity, essential for processing and release of interleukin-1ß and pyroptotic cell death. As endogenous NLRP3 activating triggers are hallmarks of many human chronic inflammatory diseases, inhibition of NLRP3 has emerged as a therapeutic target. Here we identify NDT-19795 as a novel carboxylic acid-containing NLRP3 activation inhibitor in both human and mouse monocytes and macrophages. Remarkably, conversion of the carboxylate to an isopropyl-ester (NT-0796) greatly enhances NLRP3 inhibitory potency in human monocytes. This increase is attributed to the ester-containing pharmacophore being more cell-penetrant than the acid species and, once internalized, the ester being metabolized to NDT-19795 by carboxylesterase-1 (CES-1). Mouse macrophages do not express CES-1, and NT-0796 is ineffective in these cells. Mice also contain plasma esterase (Ces1c) activity which is absent in humans. To create a more human-like model, we generated a mouse line in which the genome was modified, removing Ces1c and replacing this segment of DNA with the human CES-1 gene driven by a mononuclear phagocyte-specific promoter. We show human CES-1 presence in monocytes/macrophages increases the ability of NT-0796 to inhibit NLRP3 activation both in vitro and in vivo. As NLRP3 is widely expressed by monocytes/macrophages, the co-existence of CES-1 in these same cells affords a unique opportunity to direct ester-containing NLRP3 inhibitors precisely to target cells of interest. Profiling NT-0796 in mice humanized with respect to CES-1 biology enables critical modeling of the pharmacokinetics and pharmacodynamics of this novel therapeutic candidate. SIGNIFICANCE STATEMENT: Inhibition of NLRP3 represents a desirable therapeutic strategy for the treatment of multiple human disorders. In this study pharmacological properties of a structurally-novel, ester-containing NLRP3 inhibitor NT-0796 are characterized. To study pharmacodynamics of NT-0796 in vivo, a mouse line was engineered possessing more human-like traits with respect to carboxylesterase biology. In the context of these hCES-1 mice, NT-0796 serves as a more effective inhibitor of NLRP3 activation than the corresponding acid, highlighting the full translational potential of the ester strategy.


Assuntos
Proteína 3 que Contém Domínio de Pirina da Família NLR , Proteínas NLR , Humanos , Animais , Camundongos , Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismo , Domínio Pirina , Inflamassomos/metabolismo , Caspase 1/metabolismo , Ésteres , Hidrolases de Éster Carboxílico/metabolismo , Interleucina-1beta/metabolismo
4.
J Med Chem ; 66(21): 14897-14911, 2023 11 09.
Artigo em Inglês | MEDLINE | ID: mdl-37874905

RESUMO

The NLRP3 inflammasome is a component of the innate immune system involved in the production of proinflammatory cytokines. Neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, have been shown to have a component driven by NLRP3 inflammasome activation. Diseases such as these with large unmet medical needs have resulted in an interest in inhibiting the NLRP3 inflammasome as a potential pharmacological treatment, but to date, no marketed drugs specifically targeting NLRP3 have been approved. Furthermore, the requirement for CNS-penetrant molecules adds additional complexity to the search for NLRP3 inflammasome inhibitors suitable for clinical investigation of neuroinflammatory disorders. We designed a series of ester-substituted carbamate compounds as selective NLRP3 inflammasome inhibitors, leading to NT-0796, an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 was shown to be a potent and selective NLRP3 inflammasome inhibitor with demonstrated in vivo brain penetration.


Assuntos
Inflamassomos , Proteína 3 que Contém Domínio de Pirina da Família NLR , Humanos , Inflamassomos/metabolismo , Proteína 3 que Contém Domínio de Pirina da Família NLR/fisiologia , Doenças Neuroinflamatórias , Encéfalo/metabolismo , Ésteres
5.
ACS Med Chem Lett ; 13(8): 1321-1328, 2022 Aug 11.
Artigo em Inglês | MEDLINE | ID: mdl-35978696

RESUMO

The NLRP3 inflammasome is a multiprotein complex that facilitates activation and release of the proinflammatory cytokines interleukin-1ß (IL-1ß) and IL-18 in response to infection or endogenous stimuli. It can be inappropriately activated by a range of danger signals resulting in chronic, low-grade inflammation underlying a multitude of diseases, such as Alzheimer's disease, Parkinson's disease, osteoarthritis, and gout. The discovery of potent and specific NLRP3 inhibitors could reduce the burden of several common morbidities. In this study, we identified a weakly potent triazolopyrimidone hit (1) following an in silico modeling exercise. This was optimized to furnish potent and selective small molecule NLRP3 inflammasome inhibitors. Compounds such as NDT-30805 could be useful tool molecules for a scaffold-hopping or pharmacophore generation project or used as leads toward the development of clinical candidates.

6.
Bioorg Med Chem Lett ; 30(23): 127560, 2020 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-32956781

RESUMO

The NLRP3 inflammasome is a component of the innate immune system involved in the production of proinflammatory cytokines. Aberrant activation by a wide range of exogenous and endogenous signals can lead to chronic, low-grade inflammation. It has attracted a great deal of interest as a drug target due to the association with diseases of large unmet medical need such as Alzheimer's disease, Parkinson's disease, arthritis, and cancer. To date, no drugs specifically targeting inhibition of the NLRP3 inflammasome have been approved. In this work, we used the known NLRP3 inflammasome inhibitor CP-456,773 (aka CRID3 or MCC 950) as our starting point and undertook a Structure-Activity Relationship (SAR) analysis and subsequent scaffold-hopping exercise. This resulted in the rational design of a series of novel ester-substituted urea compounds that are highly potent and selective NLRP3 inflammasome inhibitors, as exemplified by compounds 44 and 45. It is hypothesized that the ester moiety acts as a highly permeable delivery vehicle and is subsequently hydrolyzed to the carboxylic acid active species by carboxylesterase enzymes. These molecules are greatly differentiated from the state-of-the-art and offer potential in the treatment of NLRP3-driven diseases, particularly where tissue penetration is required.


Assuntos
Ésteres/farmacologia , Indenos/farmacologia , Inflamassomos/antagonistas & inibidores , Proteína 3 que Contém Domínio de Pirina da Família NLR/antagonistas & inibidores , Ureia/análogos & derivados , Ureia/farmacologia , Animais , Sangue/metabolismo , Desenho de Fármacos , Estabilidade de Medicamentos , Ésteres/síntese química , Ésteres/metabolismo , Furanos , Compostos Heterocíclicos de 4 ou mais Anéis/química , Humanos , Indenos/síntese química , Indenos/metabolismo , Camundongos , Estrutura Molecular , Relação Estrutura-Atividade , Sulfonamidas , Sulfonas/química , Células THP-1
7.
Front Immunol ; 8: 560, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28555139

RESUMO

Treatments to limit T cell activation are essential for managing autoimmune and inflammatory disorders. The B subunit of Escherichia coli heat-labile enterotoxin (EtxB) is known to ameliorate inflammatory disease in vivo but the mechanism by which this is mediated is not well understood. Here, we show that following intranasal administration, EtxB acts on two key cellular regulators of T cell activation: regulatory T cells and dendritic cells (DCs). EtxB enhances the proliferation of lung regulatory T cells and doubles their suppressive function, likely through an increase in expression of the Treg effector molecule CTLA-4. EtxB supports the generation of interleukin-10-producing DCs that are unable to activate T cells. These data show, for the first time, that mucosal EtxB treatment limits T cells activation by acting jointly on two distinct types of immune cells.

8.
ACS Med Chem Lett ; 7(8): 768-73, 2016 Aug 11.
Artigo em Inglês | MEDLINE | ID: mdl-27563401

RESUMO

CZ415, a potent ATP-competitive mTOR inhibitor with unprecedented selectivity over any other kinase is described. In addition to a comprehensive characterization of its activities in vitro, in vitro ADME, and in vivo pharmacokinetic data are reported. The suitability of this inhibitor for studying in vivo mTOR biology is demonstrated in a mechanistic mouse model monitoring mTOR proximal downstream phosphorylation signaling. Furthermore, the compound reported here is the first ATP-competitive mTOR inhibitor described to show efficacy in a semitherapeutic collagen induced arthritis (CIA) mouse model.

9.
J Atten Disord ; 16(8): 664-74, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22090395

RESUMO

OBJECTIVE: Preclinical models, receptor localization, and genetic linkage data support the role of D4 receptors in the etiology of ADHD. This proof-of-concept study was designed to evaluate MK-0929, a selective D4 receptor antagonist as treatment for adult ADHD. METHOD: A randomized, double-blind, placebo-controlled, crossover study was conducted in adults with primary ADHD. The primary end point was changed from baseline in total score on the Adult ADHD Investigator Symptom Rating Scale following a 4-week treatment regimen. Additional measures included Clinical Global Impression-Severity Scale, Hospital Anxiety and Depression Scale, and Brown Attention Deficit Disorder Scale and D4 genotype analysis. RESULTS: No statistically significant treatment differences were found between MK-0929 and placebo in any of the primary or secondary assessments. CONCLUSION: Results from this study suggest that blockade of the D4 receptor alone is not efficacious in the treatment of adult ADHD.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Antagonistas de Dopamina/uso terapêutico , Adolescente , Adulto , Estudos Cross-Over , Antagonistas de Dopamina/farmacologia , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Índice de Gravidade de Doença , Resultado do Tratamento
10.
Biopharm Drug Dispos ; 28(6): 275-82, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17570124

RESUMO

The in vivo occupancy of brain benzodiazepine binding sites by compounds A and B was measured using a [(3)H]Ro 15-1788 binding assay and related to plasma and brain drug concentrations. The plasma concentration associated with 50% occupancy was higher for compound A than compound B (73 and 3.7 nM, respectively), however, there was little difference in the brain concentrations required (73 and 63 nM). Both compounds showed a non-linear relationship between plasma and brain concentrations such that above brain concentrations of approximately 100 nM increasing plasma concentrations did not result in a concomitant increase in brain concentrations. This is consistent with brain concentrations being dependent on a saturable compartment which was postulated to be the benzodiazepine binding site-containing GABA(A) receptors. This hypothesis was tested in alpha1H101R mice, in which the alpha1 subunit of the GABA(A) receptor is rendered insensitive to benzodiazepine binding resulting in an approximate 50% reduction in the total benzodiazepine-containing GABA(A) receptor population. It was shown that the Occ(50) brain concentrations in the alpha1H101R animals was lower (17 nM) than in wild type mice (63 nM), as was the plateau concentration in the brain (105 and 195 nM, respectively). These data suggest measured concentrations of compounds A and B in brain tissue are dependent on receptor expression with a minimal contribution from unbound and non-specifically bound compound.


Assuntos
Benzodiazepinas/metabolismo , Encéfalo/metabolismo , Ligantes , Receptores de GABA-A/metabolismo , Administração Oral , Animais , Ansiolíticos/administração & dosagem , Ansiolíticos/metabolismo , Ansiolíticos/farmacocinética , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/metabolismo , Anticonvulsivantes/farmacocinética , Benzodiazepinas/administração & dosagem , Benzodiazepinas/farmacocinética , Benzodiazepinonas/administração & dosagem , Benzodiazepinonas/metabolismo , Benzodiazepinonas/farmacocinética , Sítios de Ligação , Ligação Competitiva/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Química Encefálica , Relação Dose-Resposta a Droga , Flumazenil/administração & dosagem , Flumazenil/metabolismo , Flumazenil/farmacocinética , Flunitrazepam/administração & dosagem , Flunitrazepam/metabolismo , Flunitrazepam/farmacocinética , Moduladores GABAérgicos/administração & dosagem , Moduladores GABAérgicos/metabolismo , Moduladores GABAérgicos/farmacocinética , Agonistas de Receptores de GABA-A , Injeções Intravenosas , Masculino , Camundongos , Camundongos Mutantes , Piridazinas/administração & dosagem , Piridazinas/metabolismo , Piridazinas/farmacocinética , Ratos , Ratos Sprague-Dawley , Receptores de GABA-A/genética , Distribuição Tecidual , Triazinas/administração & dosagem , Triazinas/metabolismo , Triazinas/farmacocinética
11.
Drug Metab Dispos ; 35(2): 215-20, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17093007

RESUMO

Cytochrome P450 (P450) induction may have considerable implications for drug therapy. Therefore, understanding the induction potential of a new chemical entity at an early stage in discovery is crucial to reduce the risk of failure in the clinic and help the identification of noninducing chemical structures. Availability of human viable tissue often limits evaluation of induction potential in human hepatocytes. A solution is to increase the time period during which the hepatocytes remain viable. In this study we have investigated the induction of several P450 isozymes in long-term cultured hepatocytes compared with short-term cultured hepatocytes from the same individuals. Short- and long-term cultured primary hepatocytes isolated from each individual were cultured in a 96-well format and treated for 24 h with a range of prototypical P450 inducers and Merck Research Laboratories compounds. CYP3A4, 1A1, 1A2, 2B6, and 2C9 mRNA levels were measured using quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan) from the same cultured hepatocyte wells. CYP3A4, 1A1, 1A2, 2B6, and 2C9 were shown to be inducible in long-term cultured hepatocytes. The -fold induction varied between donors, and between short- and long-term cultured hepatocytes from the same donor. However, this variability can be controlled by normalizing data from each hepatocyte preparation to a positive control. The use of long-term cultured hepatocytes on 96-well plates has proven to be sensitive, robust, and convenient for assessing P450 induction potential of new compound entities during the drug discovery process.


Assuntos
Sistema Enzimático do Citocromo P-450/biossíntese , Hepatócitos/enzimologia , Hidrocarboneto de Aril Hidroxilases/biossíntese , Células Cultivadas , Citocromo P-450 CYP1A1/biossíntese , Citocromo P-450 CYP1A2/biossíntese , Citocromo P-450 CYP2B6 , Citocromo P-450 CYP2C9 , Citocromo P-450 CYP3A , Sistema Enzimático do Citocromo P-450/genética , Indução Enzimática , Humanos , Oxirredutases N-Desmetilantes/biossíntese , RNA Mensageiro/análise
12.
Anal Biochem ; 351(2): 266-72, 2006 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-16473319

RESUMO

Idiosyncratic adverse drug reactions (ADRs) are one of the most common causes of pharmaceutical withdrawals and labeling changes. Most ADRs are caused by drugs that form reactive species that can bind covalently to macromolecules such as proteins. The current methodology for the measurement of covalent binding relies on the use of radiolabeled material that requires an investment in time and resources not typically expended until later in the discovery process. Efforts are also made to identify reactive intermediates by the use of chemical trapping agents, such as reduced glutathione and cyanide, to form stable adducts that are characterized by liquid chromatography-tandem mass spectrometry and/or nuclear magnetic resonance spectroscopy. Here, we describe a high-throughput assay for the measurement of reactive intermediate formation. The method involves incubation of cold compound with liver microsomes in the presence of [14C]potassium cyanide. Hard electrophilic species would react with the trapping agent, resulting in the formation of a radiolabeled conjugate. Unreacted trapping agent is removed using solid-phase extraction, and the amount of radiolabeled conjugate present is determined by liquid scintillation counting. This newly developed screen has proved to be specific, sensitive, robust, and a powerful tool for assessing bioactivation potential.


Assuntos
Biotransformação , Microssomos Hepáticos/metabolismo , Preparações Farmacêuticas/metabolismo , Autoanálise , Radioisótopos de Carbono , Avaliação Pré-Clínica de Medicamentos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Humanos , Nicotina/metabolismo , Cianeto de Potássio , Contagem de Cintilação/métodos , Sensibilidade e Especificidade
13.
Chem Res Toxicol ; 17(1): 3-16, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14727914

RESUMO

It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity. Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Laboratories has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage. This requires a flexible approach to defining bioactivation issues in a variety of metabolism vectors and typically involves the initial use of small molecule trapping agents to define the potential for bioactivation. At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) preparations from preclinical species and human, and also in vivo, typically in the rat. This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Laboratories. The availability of a dedicated Labeled Compound Synthesis group, coupled to a close working relationship between Drug Metabolism and Medicinal Chemistry, represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.


Assuntos
Biotransformação , Indústria Farmacêutica/normas , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/metabolismo , Pesquisa/normas , Animais , Ensaios Clínicos como Assunto/normas , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos/normas , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico , Humanos , Ligação Proteica , Medição de Risco , Relação Estrutura-Atividade
14.
Drug Metab Dispos ; 31(6): 785-91, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12756213

RESUMO

The pharmacokinetics, metabolism, and brain penetration of the neurokinin 1 (NK1) receptor antagonist (substance P receptor antagonist), aprepitant (MK-0869), were examined in ferrets. This species exhibits human-type NK1receptor pharmacology and is of proven value in the identification of clinically useful drugs for the treatment of chemotherapy-induced nausea and vomiting in humans. After a single p.o. dose of aprepitant at 1 or 2 mg/kg, plasma levels of the compound were between approximately 200 and 270 ng/ml, 24 h after dosing. In the brain cortex, concentrations of aprepitant reached between approximately 80 and 150 ng/g of tissue 24 h after dosing. The predominant radioactive component present in the plasma and the brain of ferrets at 24 or 48 h after a single oral dose of [14C]aprepitant at 3 mg/kg was the parent compound itself. The slow plasma clearance of aprepitant ( approximately 1.5 ml/min/kg) and its abundance in ferret brain were in accord with its efficacy in blocking the retching and vomiting at 24 and 48 h postdose when ferrets were challenged with the emetic anticancer drug, cisplatin. When aprepitant and some of its metabolites were assessed for their in vitro binding affinity to the human NK1receptor, aprepitant demonstrated the highest affinity. Collectively, these data suggested that aprepitant, rather than its metabolites, was responsible, primarily, for the antiemetic activity of this compound in the male ferret.


Assuntos
Encéfalo/metabolismo , Furões , Morfolinas/farmacocinética , Antagonistas dos Receptores de Neurocinina-1 , Animais , Aprepitanto , Área Sob a Curva , Células CHO , Radioisótopos de Carbono , Cromatografia Líquida de Alta Pressão , Cromatografia Líquida , Clonagem Molecular , Cricetinae , Humanos , Masculino , Espectrometria de Massas , Morfolinas/sangue , Receptores da Neurocinina-1/genética , Contagem de Cintilação , Especificidade por Substrato
15.
Curr Opin Drug Discov Devel ; 6(1): 57-65, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12613277

RESUMO

Recent developments in the technologies and approaches to identify metabolites in a drug discovery environment are reviewed. Samples may be generated using either in vitro systems--typically, but not exclusively, liver subcellular fractions, such as microsomes, or whole cells, such as hepatocytes. Alternatively, metabolites are generated in vivo using excreta obtained following dosing in preclinical species. Recombinant drug metabolizing enzymes or microorganisms may offer alternate vectors. New techniques, such as the use of solid-phase microextraction, have found application in the isolation of metabolites from biological matrices. However, this is still dominated by the use of preparative chromatography, which has advanced through the use of mass-directed detection. Detection and structural elucidation by mass spectrometry have improved markedly with increases in sensitivity, allowing lower abundance metabolites to be detected, and increases in selectivity, with the use of high-resolution time-of-flight and quadrupole-time-of-flight instruments. Finally, higher field strength magnets coupled with novel probe designs and increased use of liquid chromatographic hyphenation techniques continue to drive the capabilities of nuclear magnetic resonance spectroscopy as the definitive structural elucidation tool.


Assuntos
Preparações Farmacêuticas/metabolismo , Farmacologia/métodos , Animais , Biotransformação , Eletroforese Capilar , Humanos , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Farmacocinética
16.
Drug Metab Dispos ; 30(8): 937-43, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12124313

RESUMO

[3R,5R,6S]-3-(2-cyclopropyloxy-5-trifluoromethoxyphenyl)-6-phenyl-1-oxa-7-azaspiro[4.5]decane is a substance P (Neurokinin 1 receptor) antagonist. Substance P antagonists are proven in concept to have excellent potential for the treatment of major depression, and they allow superior and sustained protection from acute and delayed chemotherapy-induced emesis. The metabolism of this compound was investigated in rat hepatocytes, and circulating rat plasma metabolites were identified following oral and intravenous dosing. The turnover in rat hepatocytes within 4 h was about 30%, and the major metabolites were identified as two nitrones and a lactam associated with the piperidine ring. Although these metabolites were also observed in rat plasma, the major circulating metabolite was a keto acid following oxidative de-amination of the piperidine ring. Liquid chromatography/tandem mass spectrometry and nuclear magnetic resonance were used to confirm the structure of the latter metabolite. A mechanism leading to the formation of the keto acid metabolite has been suggested, and most intermediates were observed in rat plasma.


Assuntos
Compostos Aza/sangue , Compostos Aza/metabolismo , Hepatócitos/metabolismo , Antagonistas dos Receptores de Neurocinina-1 , Compostos de Espiro/sangue , Compostos de Espiro/metabolismo , Substância P/antagonistas & inibidores , Administração Oral , Animais , Compostos Aza/farmacologia , Cromatografia Líquida , Técnicas In Vitro , Injeções Intravenosas , Cetoácidos/sangue , Espectroscopia de Ressonância Magnética , Masculino , Microssomos Hepáticos/metabolismo , Ratos , Ratos Sprague-Dawley , Compostos de Espiro/farmacologia
17.
Anal Chem ; 74(8): 1896-902, 2002 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-11985324

RESUMO

A four-channel multiplexed electrospray inlet system (MUX) coupled to a triple quadrupole mass spectrometer was investigated as a higher throughput approach to quantitative analysis. Four discrete samples may be simultaneously analyzed by virtue of a rotating sampler with a concomitant 4-fold increase in analytical throughput. Although absolute sensitivity was reduced using the MUX interface compared with analysis using traditional single electrospray interface, reproducibility of response was shown to be comparable. Source robustness was established for the analysis of both aqueous drug standards and drugs in biological media, and linearity of response for a test compound, diazepam, was demonstrated over 2 orders of magnitude. Analyte-dependent response differences were exhibited between the four channels of the interface, and this led to the overall conclusion that samples to be compared quantitatively must be analyzed through the same sprayer. In addition, each channel must be independently calibrated to afford true quantification. Should a deuterated internal standard be employed, however, quantitative comparisons can be made across channels. An HPLC pumping system providing individual back-pressure regulation to each channel was shown to provide adequate chromatography even in the event of a channel blockage. Furthermore, following multiple injections of biological samples onto the MUX interface, an eluent flow diversion was integrated into the first part of each analytical run. This served to prevent source fouling, and thus, no detrimental effects to response reproducibility or sensitivity were observed.


Assuntos
Diazepam/química , Moduladores GABAérgicos/química , Cromatografia Gasosa-Espectrometria de Massas/métodos , Espectrometria de Massas por Ionização por Electrospray/métodos , Clozapina/química , Nitrazepam/química
18.
Rapid Commun Mass Spectrom ; 16(11): 1065-71, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-11992509

RESUMO

This report presents a highly automated procedure for the determination of drug concentrations in plasma samples. The method is generic, in that it has been applied without adaptation to many different drug candidate molecules, but is also flexible, in that variations in the nature and number of samples to be analyzed can be readily accommodated. The method includes preparation of dilutions of analyte stock solutions, spiking these into control plasma to generate analytical standards, and preparation of samples suitable for analysis by high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) by precipitation of plasma proteins with acetonitrile, centrifugation, and dilution of the supernatants with HPLC buffer. All of these steps, apart from centrifugation, are performed without manual intervention on an automated liquid-handling workstation using 96-well plates. Analysis is by HPLC/MS/MS, using a generic HPLC gradient. Commercially available software was used for optimization of parameters for analysis by HPLC/MS/MS, integration of chromatographic peaks, and quantification of drug concentrations. The use of this methodology in our laboratory has greatly facilitated the analysis of small sample sets for a large number of analytes, a situation regularly encountered in an early drug discovery environment.


Assuntos
Proteínas Sanguíneas/química , Cromatografia Líquida de Alta Pressão/métodos , Avaliação de Medicamentos/métodos , Espectrometria de Massas/métodos , Preparações Farmacêuticas/sangue , Humanos , Software
19.
J Biochem Biophys Methods ; 54(1-3): 275-86, 2002 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-12543504

RESUMO

The enantiomeric separation of a series of 2-arylindoles, developed as 5HT(2A) receptor antagonists for the treatment of schizophrenia, was investigated. Evaluation of a number of chiral stationary phases (CSPs) suggested that Chiralcel OD-H and Chiralpak AD were the most versatile for these compounds, and were employed for more detailed studies. A degree of complementarity between the CSPs was observed, such that Chiralcel OD-H was more effective for piperidine-containing molecules and Chiralpak AD for piperazine- and morpholine-containing molecules. The presence of a basic secondary amine was detrimental chromatographically, but resolution was improved substantially by employing diethylamine (DEA) in the mobile phase. All separations were either enthalpy-controlled or showed no temperature dependence. Differential temperature effects between series highlighted the possibility of multiple binding modes on these CSPs. Based on this study, it is possible to make a more rational selection of chromatographic conditions for future novel analogues.


Assuntos
Amilose/análogos & derivados , Carbamatos , Celulose/análogos & derivados , Cromatografia Líquida de Alta Pressão/métodos , Indóis/isolamento & purificação , Fenilcarbamatos , Cromatografia Líquida de Alta Pressão/instrumentação , Indóis/análise , Indóis/química , Indóis/uso terapêutico , Polissacarídeos , Reprodutibilidade dos Testes , Esquizofrenia/tratamento farmacológico , Sensibilidade e Especificidade , Coloração e Rotulagem/métodos , Estereoisomerismo , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...